What question did this study set out to answer?

Examine the clinical applicability of the BT2-NPS in differentiating neuropsychiatric symptoms across the Alzheimer’s disease continuum.

Clinical applicability of the BT2-NPS for assessing neuropsychiatric symptoms across the Alzheimer’s disease continuum

View Full Paper

Ask AI

Bookmark

Examine the clinical applicability of the BT2-NPS in differentiating neuropsychiatric symptoms across the Alzheimer’s disease continuum.
Assessed 144 participants (37 healthy controls, 31 aMCI, 76 AD) aged 60-85 using BT2-NPS.
Utilized Quade's test to analyze differences in scores across diagnostic groups while controlling for age and education.
Explored partial convergent validity with the Goldberg Anxiety and Depression Scale.
BT2-NPS Total score significantly differentiated diagnostic groups and Global Deterioration Scale stages.
Identified three distinct symptom patterns: Severity-Dependent, Inverted-U, and Late-Emergence Patterns.
Weak correlations with self-reported GADS were noted, indicating complexity in symptom expression.

No takes yet. Share an insight, caveat, or question.

Randomized trial examines BT2-NPS utility for assessing neuropsychiatric symptoms in Alzheimer’s continuum, suggesting tailored care approaches.

Carrión et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial examines BT2-NPS utility for assessing neuropsychiatric symptoms in Alzheimer’s continuum, suggesting tailored care approaches.